COMMUNIQUÉS West-GlobeNewswire

Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
13/08/2026
Eikon announced seven abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting progress across Eikon’s oncology portfolio, including clinical updates for EIK1001 [...]
Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
13/08/2026
Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), continues enrolling with interim analysis on [...]
FocalTherics™ Reports Second Quarter 2026 Financial Results
13/08/2026
39% Revenue Increase and 47% Growth in U.S. Procedures FocalTherics™ Reports Second Quarter 2026 Financial Results 39% Revenue Increase and 47% Growth in U.S. Procedures AUSTIN, Texas, Aug. 13, 2026 (GLOBE NEWSWIRE) -- [...]
Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances
13/08/2026
Company launches Flora Sync LF5™, the company's first directly commercialized product, began generating revenue in July DARE to PLAY™ Sildenafil Cream progressing toward national dispensing and initial revenue in the [...]
Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
13/08/2026
SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing coronary artery disease (CAD), today reported financial results for the second [...]
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
13/08/2026
Presented first-in-human clinical imaging and dosimetry data for AKY-2519, supporting a broad clinical development program in patients with prostate, lung, and other B7-H3 expressing solid tumors Enrolling patients in [...]
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
13/08/2026
Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor in metastatic [...]
Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
13/08/2026
– ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO – – Alumis remains on track to submit its New Drug Application to FDA for [...]
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results
13/08/2026
$26.2 million in U.S. neffy ® net product revenue in Q2 2026; total U.S. epinephrine market share for Type 1 allergies of 5% and 8% share within field-targeted accounts Commercial investment realigned toward targeted [...]
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
13/08/2026
-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Olvi-Vec systemic development programs continue to advance, with additional dose-escalation updates [...]
Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results
13/08/2026
TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported [...]
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
13/08/2026
AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027 Compelling ASCO 2026 preclinical data further differentiates PH1 mechanism in KRAS-mutated [...]
Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process
13/08/2026
Late-breaking Phase 2 CAD-1005 data presented at ISTH support a late-stage portfolio organized around preoperative safety, orphan regulatory acceleration, and postoperative shielding PONTE VEDRA, Fla., Aug. 13, 2026 ( [...]
Profound Medical Launches ‘Let's Huddle’, a Global Community Supporting Men Throughout Their Prostate Care Journey
13/08/2026
A patient-centered initiative focused on education, connection, and support TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage [...]
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
13/08/2026
Enrollment and dosing completed in Cohort 1 of Phase 1b registrational study of SER-252 - Top-line data from the single-ascending-dose arm targeted for the first half of 2027 - Appointment of Farrell Simon, Pharm.D., to [...]
Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results
13/08/2026
Independent Blinded Survey of 50 Plastic Surgeons Validates Demand; NXT-41 and NXT-41x Remain On-Track Funded through launch: secured up to $26 million of capital without an equity offering The unmet need is real: 86% [...]
Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
13/08/2026
REVTORPYK™ (gedatolisib) approved by the U.S. FDA for the treatment of HR+/HER2- PIK3CA Wild-Type locally advanced or metastatic breast cancer on July 14, 2026; on track for commercial launch late third quarter 2026 [...]
Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights
13/08/2026
Achieved Q2 2026 PEMGARDA ® (pemivibart) net product revenue of $14.3 million, representing 21% growth versus Q2 2025 net product revenue of $11.8 million Completed rapid enrollment in VYD2311 DECLARATION clinical trial [...]
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
13/08/2026
RADNOR, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in [...]

Pages